Donate For Public and Patients Store Search

C017 - Dermatology Review: Skin Cancer, Surgical, and Cosmetic

Saturday, March 2; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Manage squamous cell carcinoma , melanoma and rare cancers according to the latest evidence.
  • Use multimedia tools and behavioral science to better address patients concerns.
  • Optimize your resurfacing and injectable practice.

Description

We will cover the hot topics in both skin cancer and the cosmetic practice of dermatologic surgery. We will get an update on the staging and management of squamous cell carcinoma and melanoma. We will also review preliminary guidelines for rare cutaneous cancers such as sebaceous carcinoma and adenexal carcinoma. We will review the use of videos to enhance patient understanding. We will have an in-depth lecture from an expert on behavioral science to help us better interface with our patient population. Finally we have experts in cosmetic dermatologic surgery giving pearls and guidance in regards to resurfacing and their injectible practice.

Disclosures

  • Alam, Murad, MD: Pulse Biosciences – C(Fees);
  • Belcher, Matthew, MD: no financial relationships exist with commercial interests.
  • Butterwick, Kimberly J., MD: Allergan, Inc – I(Grants/Research Funding); Allergan, Inc. – A(H); Colorescience – A(H); Evolus, Inc. – A(H); Galderma Laboratories, L.P. – A(H), I(Grants/Research Funding); Histogen Inc. – I(Grants/Research Funding); Merz Pharmaceuticals, LLC – A(H); Revance Therapeutics, Inc. – A(H); Sinclair Pharma, LLC – Speaker/Faculty Education(H);
  • Decker, Ashley, MD: no financial relationships exist with commercial interests.
  • Lawrence, Naomi, MD: no financial relationships exist with commercial interests.
  • Matarasso, Seth L., MD: no financial relationships exist with commercial interests.
  • Rieder, Evan, MD: BMS – C(Fees); UCB – Data Safety Monitoring Board(Fees); Unilever – C(Fees);
  • Riis, Jason: Endo Pharmaceuticals – C(Fees); Pfizer Inc. – C(Fees);
  • Saedi, Nazanin A., MD: Aerolase – I(EQ); Alastin Skincare, Inc – C(Fees); Cartessa Aesthetics – C(EQ); Cynosure, Inc – O(EQ);
  • Waldman, Abigail Baird, MD: La Roche-Posay Laboratorie Pharmaceutique – I(Grants/Research Funding);
Schedule
Saturday, March 2
1:00 PM
Dr. Lawrence / Welcome
1:05 PM
Dr. Waldman / Squamous cell carcinoma management
1:20 PM
Dr. Belcher / Malignant melanoma update
1:35 PM
Dr. Alam / Guidelines for difficult cancers
1:50 PM
Dr. Decker / Multimedia approach to patient care
2:05 PM
Dr. Waldman, Dr. Belcher, Dr. Alam, and Dr. Decker / questions
2:15 PM
/ break
2:20 PM
Dr. Rieder / Protecting your patients and yourself: practical tips for managing body dysmorphic disorder
2:35 PM
Riis / Consumers and patients: Insights from behavioral science
3:05 PM
Dr. Butterwick / Laser resurfacing Balancing treatment with downtime with patient expectations
3:20 PM
Dr. Saedi / Acquiring new devices: How to assess to value and efficacy
3:35 PM
Dr. Matarasso / Pearls for chemical peels and soft tissue injectables
3:50 PM
Dr. Butterwick, Riis, Dr. Saedi, Dr. Matarasso, and Dr. Rieder / final questions
Event Details
  • Date
    Saturday, March 2
  • Time
    1:00 PM - 4:00 PM
  • Location
    Room 147B
  • CME Credits
    3.00
  • Type
    Ticketed
Directors/Co-Directors
  • Naomi Lawrence, MD, FAAD
Speakers
  • Abigail Baird Waldman, MD, FAAD
  • Ashley Decker, MD, FAAD
  • Evan Rieder, MD, FAAD - Handout
  • Jason Riis
  • Kimberly J. Butterwick, MD, FAAD
  • Matthew Belcher, MD, FAAD
  • Murad Alam, MD, FAAD
  • Nazanin A. Saedi, MD, FAAD
  • Seth L. Matarasso, MD, FAAD